US Denies Coherus’ Petitions Challenging AbbVie’s Patent for Humira

September 15, 2017: By Jon Swedien

legal issuesThe US Patent Trial and Appeal Board has denied Coherus BioSciences’ four petitions seeking invalidation of a Humira patent held by Chicago-based AbbVie, Coherus announced Sept. 7.

Humira (adalimumab) posted sales of $16 billion in 2016, accounting for most of AbbVie’s revenues.

The anti-inflammatory drug is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and several other diseases and medical conditions.

In June 2016, the FDA approved Humira as a treatment for noninfectious intermediate and posterior uveitis and panuveitis.

The drug is protected by several patents that run through 2022.

Coherus prevailed in May in a petition against a different Humira patent.

The Redwood City, California, company has created a biosimilar version of Humira, CHS-1420.

Coherus planned to file for US approval of its biosimilar in the first half of 2018.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022